•
Nanomedicines have found extensive applications in clinics for cancer theranostic.
•
They modify PK and biodistribution of the conventional drugs, and reduce their systemic toxicity.
•
In practice, nanomedicine could improve clinical outcome and patient’s survival.
•
Patient pre-selection based on the extent of EPR and target receptors is recommended.